Dr Cecelia Gzell

BMedSc, BMed, PhD, FRANZCR

Radiation Oncologist

Spoken languages

English

Special clinical interest in central nervous system tumours.

Dr Gzell has completed undergraduate degrees in both Medical Science (University of Sydney, 1998) and Medicine (University of Newcastle, 2003).  She undertook Radiation Oncology Specialist training primarily at Royal Prince Alfred Hospital (2006-2011) prior to becoming a fellow of the Royal Australian and New Zealand College of Radiologists (Faculty of Radiation Oncology) in 2011. Between 2012-2014 she undertook a post-graduate fellowship in Neuro-Oncology at Royal North Shore Hospital with research and publications in glioblastomas culminating in a PhD thesis entitled: Optimising outcomes in patients with glioblastoma receiving radiotherapy (2017).

In 2014 Dr Gzell joined Genesis Cancer Care and works as a Radiation Oncologist at St Vincents, and Macquarie University Hospitals.  She has Honorary appointments at these hospitals as well as Concord General Repatriation Hospital.  She has a busy Neuro-Oncology practice and started a Multidisciplinary Neuro-Oncology MDT (Multidisciplinary Team Meeting) at St Vincents Hospital.  She attends Neuro-Oncology MDTs at St Vincent’s (Chair of the meeting), Macquarie, and Concord Hospitals.  She also attends the Pituitary MDT at Macquarie Hospital.  She has opened Neuro-oncology based clinical trials at St Vincents hospital.

Dr Gzell has been involved with the Co-operative Trials Group for Neuro-Oncology (COGNO) since becoming a member in 2011.  In 2014 she was on the Annual Scientific Meeting (ASM) Organising committee and was the Convenor of the ASM in 2015.  In 2016 she was the Co-Convenor of the combined COGNO-ASNO (Asian Society of Neuro-Oncology) ASM and Chair of the Stereotactic Radiosurgery Workshop.  She was appointed to the COGNO Management Committee in 2016.  Dr Gzell is a full member of the Society of Neuro-Oncology (SNO, USA) and a founding member of the Stereotactic Interest Group of Australasia (SIGA).

Her main focus is the best management of both primary and secondary central nervous system neoplasms utilising modern techniques including stereotactic radiosurgery and gamma knife surgery.

Awards received

  • COGNO best Oral presentation award 2014
  • NHMRC Clinical Trials Concept Development Scholarship 2011

Clinical interests

Dr Gzell is also interested in advanced imaging in radiation oncology.

Publications & affiliations

  • Gzell C, Back M, Wheeler HR, Bailey D, & Foote M. Radiotherapy in glioblastoma: past, present, and future, Clinical Oncology (Impact factor 3.398), 29(1):15-25, January 2017
  • Gzell C, Wheeler H, McCloud P, Kastelan M, & Back M, Small increases in enhancement on MRI may predict survival post radiotherapy in patients with glioblastoma, Journal of Neuro-Oncology (Impact factor 3.070), 128(1):67-74, May 2016
  • Gzell C, Wheeler H, Huang D, Gaur P, Chen J, Kastelan M, & Back M, Proliferation index rather than presence of residual tumour predicts for median survival following second craniotomy within six months of adjuvant radiation therapy for high grade glioma, Clinical Oncology (Impact factor 3.398) 28(3): 215-222, September 2015
  • Gzell C, Wheeler H, Guo L, Kastelan M, & Back M, Elderly patients aged 65 to 75 years with Glioblastoma Multiforme may benefit from long course radiation therapy with temozolomide, Journal of Neuro-Oncology (Impact factor 2.787), 119(1): 187-196, July 2014
  • Gzell C, Wheeler H, Guo L, Kastelan M, & Back M, Employment following chemoradiotherapy in glioblastoma: a prospective case series, Journal of Cancer Survivorship (Impact factor 3.570), 8(1):108-13, March 2014

Professional memberships

  • FRANZCR
  • Society of Neuro-Oncology (SNO)
  • Co-operative trials group of Neuro-Oncology (COGNO)
  • International Stereotactic Radiosurgery Society (ISRS)
  • Stereotactic interest group of Australasia (SIGA)